CN1976701A - 毒蕈碱性乙酰胆碱受体拮抗剂 - Google Patents

毒蕈碱性乙酰胆碱受体拮抗剂 Download PDF

Info

Publication number
CN1976701A
CN1976701A CNA2005800215360A CN200580021536A CN1976701A CN 1976701 A CN1976701 A CN 1976701A CN A2005800215360 A CNA2005800215360 A CN A2005800215360A CN 200580021536 A CN200580021536 A CN 200580021536A CN 1976701 A CN1976701 A CN 1976701A
Authority
CN
China
Prior art keywords
methyl
hydroxyl
bicyclo
nitrogen
octane bromide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800215360A
Other languages
English (en)
Chinese (zh)
Inventor
德雷马尼·I·莱恩
迈克尔·R·帕洛维奇
布伦特·W·麦克利兰
克里斯托弗·E·尼普
索尼亚·M·托马斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35242158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1976701(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1976701A publication Critical patent/CN1976701A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
CNA2005800215360A 2004-04-27 2005-04-27 毒蕈碱性乙酰胆碱受体拮抗剂 Pending CN1976701A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56562304P 2004-04-27 2004-04-27
US60/565,623 2004-04-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2010105580787A Division CN102040602A (zh) 2004-04-27 2005-04-27 毒蕈碱性乙酰胆碱受体拮抗剂

Publications (1)

Publication Number Publication Date
CN1976701A true CN1976701A (zh) 2007-06-06

Family

ID=35242158

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2005800215360A Pending CN1976701A (zh) 2004-04-27 2005-04-27 毒蕈碱性乙酰胆碱受体拮抗剂
CN2010105580787A Pending CN102040602A (zh) 2004-04-27 2005-04-27 毒蕈碱性乙酰胆碱受体拮抗剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010105580787A Pending CN102040602A (zh) 2004-04-27 2005-04-27 毒蕈碱性乙酰胆碱受体拮抗剂

Country Status (38)

Country Link
US (9) US7498440B2 (enExample)
EP (3) EP3111936A1 (enExample)
JP (2) JP5014121B2 (enExample)
KR (2) KR101152032B1 (enExample)
CN (2) CN1976701A (enExample)
AP (1) AP2213A (enExample)
AR (1) AR050902A1 (enExample)
AU (1) AU2005237576B2 (enExample)
BE (1) BE2014C063I2 (enExample)
BR (1) BRPI0510170B8 (enExample)
CA (2) CA2755954C (enExample)
CY (3) CY1113196T1 (enExample)
DK (2) DK1740177T3 (enExample)
EA (2) EA015033B1 (enExample)
EC (1) ECSP066940A (enExample)
ES (2) ES2600405T3 (enExample)
FR (1) FR14C0075I2 (enExample)
HR (2) HRP20120832T1 (enExample)
HU (2) HUE031304T2 (enExample)
IL (1) IL178152A (enExample)
LT (1) LT2570128T (enExample)
LU (1) LU92565I2 (enExample)
MA (1) MA28631B1 (enExample)
MX (1) MXPA06012405A (enExample)
MY (1) MY144753A (enExample)
NL (1) NL300694I1 (enExample)
NO (3) NO338959B1 (enExample)
NZ (1) NZ549997A (enExample)
PE (1) PE20060259A1 (enExample)
PL (2) PL1740177T3 (enExample)
PT (2) PT2570128T (enExample)
SG (1) SG186597A1 (enExample)
SI (2) SI2570128T1 (enExample)
TW (1) TWI363759B (enExample)
UA (1) UA95768C2 (enExample)
UY (1) UY28871A1 (enExample)
WO (1) WO2005104745A2 (enExample)
ZA (1) ZA200608565B (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102946868A (zh) * 2010-06-22 2013-02-27 奇斯药制品公司 包含抗毒蕈碱药的干粉制剂
CN105431432A (zh) * 2013-07-13 2016-03-23 北京嘉事联博医药科技有限公司 奎宁类化合物、其光学异构体及其制备方法和医药用途
CN105461710A (zh) * 2015-10-23 2016-04-06 安徽德信佳生物医药有限公司 一种芜地溴铵的制备方法
CN105555269A (zh) * 2013-07-30 2016-05-04 葛兰素史密斯克莱知识产权发展有限公司 用于治疗过度出汗的局部组合物及其使用方法
CN107163038A (zh) * 2012-08-15 2017-09-15 葛兰素集团有限公司 化学方法
CN107200734A (zh) * 2016-03-18 2017-09-26 益方生物科技（上海）有限公司 奎宁环衍生物及其制备方法和用途
CN108558860A (zh) * 2018-06-04 2018-09-21 成都伊诺达博医药科技有限公司 一种合成芜地溴铵的新方法
CN112479983A (zh) * 2020-11-25 2021-03-12 江苏豪森药业集团有限公司 乌美溴铵中间体及其制备方法
WO2021218833A1 (zh) * 2020-04-26 2021-11-04 北京硕佰医药科技有限责任公司 一种m受体拮抗剂的晶体、制备方法及其应用

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050250A1 (es) * 2003-07-17 2005-04-08 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
AU2004281167A1 (en) * 2003-10-17 2005-04-28 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists field of the invention
PE20050489A1 (es) * 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
WO2005087236A1 (en) * 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
US20070185148A1 (en) * 2004-03-17 2007-08-09 Glaxo Group Limited M3 muscarinic acetylchoine receptor antagonists
WO2005095407A1 (en) * 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US20080194619A1 (en) * 2004-04-05 2008-08-14 Laurent Lecanu Anti-Hiv Quinuclidine Compounds
MY144753A (en) 2004-04-27 2011-10-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005112644A2 (en) * 2004-05-13 2005-12-01 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
EP1957075A4 (en) * 2004-11-15 2009-11-18 Glaxo Group Ltd NOVEL ANTAGONISTS OF ACETYLCHOLINE M3 TYPE MUSCARINIC RECEPTORS
JP2009503099A (ja) * 2005-08-02 2009-01-29 グラクソ グループ リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
JP2009504768A (ja) * 2005-08-18 2009-02-05 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
EA200801997A1 (ru) 2006-04-20 2009-04-28 Глаксо Груп Лимитед Новые соединения
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
JP2009545579A (ja) 2006-08-01 2009-12-24 グラクソ グループ リミテッド ピラゾロ［３，４−ｂ］ピリジン化合物、及びｐｄｅ４阻害薬としてのその使用
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
AR070563A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Compuesto de un biciclo condensado pirazol-piridin-amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de enfermedades respiratorias.
CL2009000248A1 (es) 2008-02-06 2009-09-11 Glaxo Group Ltd Compuestos derivados de pirazolo [3,4-b] piridin-5-il, inhibidores de la fosfodiesterasa de tipo iv (pde4) y antagonista de receptores muscarinicos de acetilcolina (machr); composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles en el tratamiento de enferemedades respiratorias y alergicas
TW201000476A (en) 2008-02-06 2010-01-01 Glaxo Group Ltd Dual pharmacophores-PDE4-muscarinic antagonistics
ES2383246T3 (es) 2008-06-05 2012-06-19 Glaxo Group Limited 4-amino-indazoles
WO2009147187A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
DK2400950T3 (da) 2009-02-26 2019-07-29 Glaxo Group Ltd Farmaceutiske formuleringer omfattende 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
ES2542551T3 (es) 2009-03-09 2015-08-06 Glaxo Group Limited 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
AU2010243613B2 (en) 2009-04-30 2015-05-07 Glaxo Group Limited Oxazole substituted indazoles as PI3-kinase inhibitors
WO2011029896A1 (en) 2009-09-11 2011-03-17 Glaxo Group Limited Methods of preparation of muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
JP2013512879A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
US20120238559A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Novel compounds
JP2013512880A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体
CA2788364C (en) * 2010-01-28 2017-10-31 Theron Pharmaceuticals, Inc. 7-azoniabicyclo[2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
PL2614058T3 (pl) 2010-09-08 2015-12-31 Glaxosmithkline Ip Dev Ltd Polimorfy i sole n-[5-[4-(5-{[(2r,6s)-2,6-dimetylo-4-morfolinylo]-metylo}-1,3-oksazol-2-ilo)-1h-indazol-6-ilo]-2-(metyloksy)-3-pirydynylo]metanosulfonamidu
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
PH12013502497A1 (en) 2011-06-08 2019-07-17 Glaxo Group Ltd Combination comprising umeclidinium and a corticosteroid
US20140116434A1 (en) 2011-06-08 2014-05-01 Glaxo Group Limited Dry Powder Inhaler Compositions
RU2666963C2 (ru) 2012-04-13 2018-09-13 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Агрегированные частицы
RU2502743C1 (ru) * 2012-08-03 2013-12-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России) Синтетический антиген, обладающий способностью связывать аутоантитела к мускариновому м2-рецептору
GB201222679D0 (en) * 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
AU2014336251A1 (en) 2013-10-17 2016-04-14 Glaxosmithkline Intellectual Property Development Limited PI3K inhibitor for treatment of respiratory disease
CN105658218A (zh) 2013-10-17 2016-06-08 葛兰素史克知识产权开发有限公司 用于治疗呼吸疾病的pi3k抑制剂
CN107072976A (zh) 2014-05-12 2017-08-18 葛兰素史克知识产权第二有限公司 用于治疗传染性疾病的包含Danirixin的药物组合物
ES2775606T3 (es) 2014-05-28 2020-07-27 Glaxosmithkline Ip Dev Ltd Furoato de fluticasona en el tratamiento de la EPOC
US10023535B2 (en) 2014-11-03 2018-07-17 Olon S.P.A. Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
US10835514B2 (en) * 2016-01-08 2020-11-17 Theron Pharmaceuticals, Inc. Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
PT109740B (pt) * 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio
WO2018163212A1 (en) * 2017-03-08 2018-09-13 Gbr Laboratories Pvt. Ltd A process for the preparation of umeclidinium bromide and intermediates thereof
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
IT201700058796A1 (it) * 2017-05-30 2018-11-30 Olon Spa Procedimento per la preparazione di un nuovo intermedio di sintesi dell’umeclidinio.
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN111511800B (zh) 2017-10-30 2023-11-28 武田药品工业株式会社 灭活脂包膜病毒的环境相容性去污剂
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
PT115583B (pt) 2019-06-17 2022-05-02 Hovione Farm S A Processo contínuo para a preparação de medicamentos anticolinérgicos
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
WO2021191875A1 (en) 2020-03-26 2021-09-30 Glaxosmithkline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections
CN111484445B (zh) * 2020-04-21 2021-05-18 广东莱佛士制药技术有限公司 分离纯化高纯度乌美溴铵的中间体的方法
IL301285A (en) 2020-09-10 2023-05-01 Precirix N V Antibody fragment against fap
PT117440B (pt) 2021-09-03 2024-04-26 Hovione Farm S A Processo para a preparação de aminas cíclicas cloroaquilo substituídas
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
CA3251753A1 (en) 2022-05-02 2023-11-09 Precirix N.V. PRE-TARGETTING
WO2024251812A1 (en) 2023-06-07 2024-12-12 Pharmazell Gmbh A process for the preparation of umeclidinium bromide intermediate

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800478A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800481A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (de) 1967-06-08 1972-04-25 Siemens Ag Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1230087A (enExample) 1967-08-17 1971-04-28
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
GB2129691B (en) 1982-10-08 1987-08-05 Glaxo Group Ltd Devices for administering medicaments to patients
FI88112C (fi) 1985-07-30 1993-04-13 Glaxo Group Ltd Anordning foer administrering av laekemedel till patienter
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5780466A (en) 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
US6350758B1 (en) 1996-12-02 2002-02-26 Georgetown University Tropane derivatives and method for their synthesis
US6248752B1 (en) 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
KR100869721B1 (ko) * 2000-12-28 2008-11-21 알미랄 에이쥐 신규한 퀴누클리딘 유도체 및 그를 함유한 의약 조성물
EP1438309A1 (en) 2001-10-17 2004-07-21 Ucb, S.A. Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
BR0214016A (pt) * 2001-11-09 2004-10-13 Upjohn Co Compostos azabicìclico-fenil-fundido heterocìclicos e seu uso como ligandos alfa 7 nachr
US7452904B2 (en) * 2001-12-20 2008-11-18 Chiesi Farmaceutici S.P.A. 1-alkyl-1-azoniabicyclo' 2.2.2 octane carbamate derivatives and their use as muscarinic receptor antagonists
US6696462B2 (en) 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
TW200410951A (en) 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
WO2004091482A2 (en) 2003-04-07 2004-10-28 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
PE20050250A1 (es) 2003-07-17 2005-04-08 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
PE20050327A1 (es) 2003-07-17 2005-06-08 Glaxo Group Ltd Derivados de 8-azoniabiciclo[3.2.1]octano como antagonistas de los receptores muscarinicos de la acetilcolina
AR048573A1 (es) 2003-07-17 2006-05-10 Glaxo Group Ltd Compuesto de 8-azoniabiciclo[3.2.1]octano sustituido en la posicion 3, composicion farmceutica que lo comprende y su uso para preparar esta ultima
JP2007508390A (ja) 2003-10-14 2007-04-05 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
AU2004281167A1 (en) 2003-10-17 2005-04-28 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists field of the invention
PE20050489A1 (es) 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
ES2329586T3 (es) 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
AR046784A1 (es) 2003-12-03 2005-12-21 Glaxo Group Ltd Compuesto de amina ciclica composicion farmaceutica que lo comprende y su uso para preparar esta ultima
AR046783A1 (es) 2003-12-03 2005-12-21 Glaxo Group Ltd Compuesto de sal ciclica de amonio cuaternario composicion farmaceutica que lo comprende y su uso para preparar esta ultima
TW200534855A (en) 2004-01-13 2005-11-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005086873A2 (en) 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2005087236A1 (en) 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
JP2007529514A (ja) 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
WO2005095407A1 (en) 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
EP1725240A4 (en) 2004-03-17 2009-03-25 Glaxo Group Ltd ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
US20070185148A1 (en) 2004-03-17 2007-08-09 Glaxo Group Limited M3 muscarinic acetylchoine receptor antagonists
US20070238751A1 (en) 2004-04-07 2007-10-11 Laine Dramane I Muscarinic Acetylcholine Receptor Antagonists
MY144753A (en) * 2004-04-27 2011-10-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005112644A2 (en) 2004-05-13 2005-12-01 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
TW200606161A (en) 2004-05-28 2006-02-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
US20080287487A1 (en) 2004-06-30 2008-11-20 Anthony William James Cooper Muscarinic Acetylcholine Receptor Antagonists
WO2006017768A2 (en) 2004-08-05 2006-02-16 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
JP2008509158A (ja) 2004-08-06 2008-03-27 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
JP2008518939A (ja) 2004-10-29 2008-06-05 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
EP1957075A4 (en) 2004-11-15 2009-11-18 Glaxo Group Ltd NOVEL ANTAGONISTS OF ACETYLCHOLINE M3 TYPE MUSCARINIC RECEPTORS
JP2008520573A (ja) 2004-11-15 2008-06-19 グラクソ グループ リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
PE20060826A1 (es) 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
PE20061162A1 (es) 2004-12-06 2006-10-14 Smithkline Beecham Corp Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
WO2006065788A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Novel muscarinic acetylcholine receptor antagonists
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
EP1937230A4 (en) 2005-08-02 2009-08-26 Glaxo Group Ltd M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
JP2009503099A (ja) 2005-08-02 2009-01-29 グラクソ グループ リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
JP2009504768A (ja) 2005-08-18 2009-02-05 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102946868B (zh) * 2010-06-22 2014-10-29 奇斯药制品公司 包含抗毒蕈碱药的干粉制剂
CN102946868A (zh) * 2010-06-22 2013-02-27 奇斯药制品公司 包含抗毒蕈碱药的干粉制剂
CN107163038B (zh) * 2012-08-15 2020-07-28 葛兰素集团有限公司 化学方法
CN107163038A (zh) * 2012-08-15 2017-09-15 葛兰素集团有限公司 化学方法
CN105431432B (zh) * 2013-07-13 2018-01-09 北京硕佰医药科技有限责任公司 奎宁类化合物、其光学异构体及其制备方法和医药用途
CN105431432A (zh) * 2013-07-13 2016-03-23 北京嘉事联博医药科技有限公司 奎宁类化合物、其光学异构体及其制备方法和医药用途
US9751875B2 (en) 2013-07-13 2017-09-05 Beijing Fswelcome Technology Development Co., Ltd. Quinine compounds, and optical isomers, preparation method and medical use thereof
CN105555269A (zh) * 2013-07-30 2016-05-04 葛兰素史密斯克莱知识产权发展有限公司 用于治疗过度出汗的局部组合物及其使用方法
CN105461710A (zh) * 2015-10-23 2016-04-06 安徽德信佳生物医药有限公司 一种芜地溴铵的制备方法
CN107200734A (zh) * 2016-03-18 2017-09-26 益方生物科技（上海）有限公司 奎宁环衍生物及其制备方法和用途
CN107200734B (zh) * 2016-03-18 2019-12-24 益方生物科技（上海）有限公司 奎宁环衍生物及其制备方法和用途
CN108558860A (zh) * 2018-06-04 2018-09-21 成都伊诺达博医药科技有限公司 一种合成芜地溴铵的新方法
CN108558860B (zh) * 2018-06-04 2020-12-25 成都伊诺达博医药科技有限公司 一种合成芜地溴铵的方法
WO2021218833A1 (zh) * 2020-04-26 2021-11-04 北京硕佰医药科技有限责任公司 一种m受体拮抗剂的晶体、制备方法及其应用
CN115397823A (zh) * 2020-04-26 2022-11-25 北京硕佰医药科技有限责任公司 一种m受体拮抗剂的晶体、制备方法及其应用
US12358908B2 (en) 2020-04-26 2025-07-15 Beijing Showby Pharmaceutical Co., Ltd. Crystals, preparation method and application of a muscarinic receptor antagonist
CN112479983A (zh) * 2020-11-25 2021-03-12 江苏豪森药业集团有限公司 乌美溴铵中间体及其制备方法
CN112479983B (zh) * 2020-11-25 2022-07-12 江苏豪森药业集团有限公司 乌美溴铵中间体及其制备方法

Also Published As

Publication number Publication date
CA2755954C (en) 2014-02-18
NO2017018I1 (no) 2017-05-04
US20130030015A1 (en) 2013-01-31
IL178152A (en) 2011-05-31
NL300694I2 (enExample) 2015-12-29
BRPI0510170B1 (pt) 2018-12-18
US20070185155A1 (en) 2007-08-09
US7498440B2 (en) 2009-03-03
AU2005237576B2 (en) 2012-01-12
EA200601991A1 (ru) 2007-02-27
HUS1400053I1 (hu) 2017-07-28
ES2600405T3 (es) 2017-02-08
US20150238470A1 (en) 2015-08-27
EA021994B1 (ru) 2015-10-30
HUE031304T2 (hu) 2017-07-28
NZ549997A (en) 2010-10-29
US8575347B2 (en) 2013-11-05
AP2213A (en) 2011-03-01
LT2570128T (lt) 2016-10-10
BE2014C063I2 (enExample) 2024-08-08
SI1740177T1 (sl) 2012-12-31
US20070249664A1 (en) 2007-10-25
US20140080863A1 (en) 2014-03-20
IL178152A0 (en) 2006-12-31
JP2012162559A (ja) 2012-08-30
EP1740177B1 (en) 2012-08-08
CA2564742A1 (en) 2005-11-10
EP2570128B1 (en) 2016-08-10
FR14C0075I1 (fr) 2014-11-21
NO338959B1 (no) 2016-11-07
TWI363759B (en) 2012-05-11
AU2005237576A1 (en) 2005-11-10
MA28631B1 (fr) 2007-06-01
ES2392848T4 (es) 2014-10-01
DK2570128T3 (en) 2016-11-07
CA2564742C (en) 2012-01-10
US8853404B2 (en) 2014-10-07
EP1740177A2 (en) 2007-01-10
DK1740177T3 (da) 2012-10-29
KR101152032B1 (ko) 2012-06-11
BRPI0510170A (pt) 2007-10-02
ZA200608565B (en) 2019-12-18
HRP20161385T1 (hr) 2016-12-02
EP2570128A1 (en) 2013-03-20
US9144571B2 (en) 2015-09-29
JP2007534769A (ja) 2007-11-29
NL300694I1 (enExample) 2015-12-29
PE20060259A1 (es) 2006-03-25
CY1118082T1 (el) 2017-06-28
KR20070015412A (ko) 2007-02-02
KR101037026B1 (ko) 2011-05-25
CA2755954A1 (en) 2005-11-10
CY1113196T1 (el) 2015-12-09
PL1740177T3 (pl) 2012-12-31
PT1740177E (pt) 2012-11-02
SG186597A1 (en) 2013-01-30
UA95768C2 (ru) 2011-09-12
EA015033B1 (ru) 2011-04-29
US8183257B2 (en) 2012-05-22
AP2006003746A0 (en) 2006-10-31
HRP20120832T1 (hr) 2012-11-30
ECSP066940A (es) 2006-12-20
JP5398871B2 (ja) 2014-01-29
WO2005104745A3 (en) 2006-08-03
CY2014043I2 (el) 2015-12-09
NO20065417L (no) 2006-12-29
WO2005104745A2 (en) 2005-11-10
EA201100019A1 (ru) 2011-12-30
UY28871A1 (es) 2005-11-30
HK1102423A1 (en) 2007-11-23
NO2017017I1 (no) 2017-05-04
FR14C0075I2 (fr) 2015-05-22
CN102040602A (zh) 2011-05-04
US20090124653A1 (en) 2009-05-14
PL2570128T3 (pl) 2017-09-29
PT2570128T (pt) 2016-10-07
US7488827B2 (en) 2009-02-10
US20120157491A1 (en) 2012-06-21
EP3111936A1 (en) 2017-01-04
US9045469B2 (en) 2015-06-02
NO2017018I2 (no) 2018-05-14
US8309572B2 (en) 2012-11-13
LU92565I9 (enExample) 2019-01-17
US20160002220A1 (en) 2016-01-07
CY2014043I1 (el) 2015-12-09
EP1740177A4 (en) 2010-05-05
MXPA06012405A (es) 2007-01-17
MY144753A (en) 2011-10-31
KR20110010841A (ko) 2011-02-07
TW200605887A (en) 2006-02-16
BRPI0510170B8 (pt) 2021-05-25
ES2392848T3 (es) 2012-12-14
SI2570128T1 (sl) 2016-11-30
AR050902A1 (es) 2006-12-06
LU92565I2 (fr) 2014-12-02
JP5014121B2 (ja) 2012-08-29
US20140371264A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
CN1976701A (zh) 毒蕈碱性乙酰胆碱受体拮抗剂
CN1230431C (zh) 用作类胰蛋白酶抑制剂的芳基甲胺衍生物
CN1250545C (zh) 新的奎宁环衍生物类及含有这类衍生物的药物组合物
CN1272334C (zh) 作为毒蕈碱性m3受体配体的奎宁环衍生物及其用途
CN1048986C (zh) 杂环化合物及其制备和用途
CN1298717C (zh) 奎宁环氨基甲酸酯衍生物及其作为m3拮抗剂的应用
CN100345847C (zh) 新的联芳基甲酰胺
CN1662527A (zh) 作为m3毒蕈碱性受体拮抗剂的吡咯烷鎓衍生物
CN1114596C (zh) 联苯基衍生物
CN1298715C (zh) 作为组胺h3拮抗剂的非咪唑化合物
CN1088917A (zh) 取代的苄氨基含氮非芳族杂环化合物
CN1203069C (zh) 经取代的哌啶,含有这些化合物的药物组合物,及其制备方法
CN1678610A (zh) 奎宁环酰胺衍生物
CN1832948A (zh) 1－烷基－1－氮鎓双环[2.2.2]辛烷氨基甲酸酯衍生物及其用作蕈毒碱受体拮抗剂的用途
CN1585749A (zh) 类大麻苷受体配体
CN1173867A (zh) 吲哚基神经肽y受体拮抗剂
CN1942465A (zh) Akt活性抑制剂
CN1161334A (zh) 新的取代胍衍生物，其制备方法和其药物用途)
CN1942470A (zh) Akt活性抑制剂
CN1571787A (zh) 奎宁环衍生物、制备它们的方法和它们作为m2和/或m3毒蕈碱受体抑制剂的用途
CN1930143A (zh) 具有微粒体甘油三酸酯传递蛋白质抑制活性的被五元杂环取代的芳基哌啶或哌嗪
CN1143848C (zh) 用作毒蕈碱性受体拮抗剂的2-芳基乙基-(哌啶-4-基甲基)胺衍生物
CN1950089A (zh) 吗啉化合物
CN1633414A (zh) 化合物
CN1740169A (zh) 用作类胰蛋白酶抑制剂的芳基甲胺衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20070606